ENTA
Price
$7.58
Change
+$0.13 (+1.74%)
Updated
Sep 17, 12:18 PM (EDT)
Capitalization
159.48M
61 days until earnings call
VRDN
Price
$18.73
Change
+$0.07 (+0.38%)
Updated
Sep 17, 12:47 PM (EDT)
Capitalization
1.47B
62 days until earnings call
Interact to see
Advertisement

ENTA vs VRDN

Header iconENTA vs VRDN Comparison
Open Charts ENTA vs VRDNBanner chart's image
Enanta Pharmaceuticals
Price$7.58
Change+$0.13 (+1.74%)
Volume$200
Capitalization159.48M
Viridian Therapeutics
Price$18.73
Change+$0.07 (+0.38%)
Volume$700
Capitalization1.47B
ENTA vs VRDN Comparison Chart in %
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. VRDN commentary
Sep 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Buy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 17, 2025
Stock price -- (ENTA: $7.45 vs. VRDN: $18.66)
Brand notoriety: ENTA and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 102% vs. VRDN: 71%
Market capitalization -- ENTA: $159.48M vs. VRDN: $1.47B
ENTA [@Biotechnology] is valued at $159.48M. VRDN’s [@Biotechnology] market capitalization is $1.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • ENTA’s TA Score: 5 bullish, 5 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ENTA and VRDN are a good buy in the short-term.

Price Growth

ENTA (@Biotechnology) experienced а -17.59% price change this week, while VRDN (@Biotechnology) price change was -7.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.53%. For the same industry, the average monthly price growth was +7.02%, and the average quarterly price growth was +36.11%.

Reported Earning Dates

ENTA is expected to report earnings on Nov 17, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+2.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.47B) has a higher market cap than ENTA($159M). ENTA YTD gains are higher at: 29.565 vs. VRDN (-2.660). ENTA has higher annual earnings (EBITDA): -82.41M vs. VRDN (-340.62M). VRDN has more cash in the bank: 563M vs. ENTA (204M). VRDN has less debt than ENTA: VRDN (21.3M) vs ENTA (58M). ENTA has higher revenues than VRDN: ENTA (64.8M) vs VRDN (305K).
ENTAVRDNENTA / VRDN
Capitalization159M1.47B11%
EBITDA-82.41M-340.62M24%
Gain YTD29.565-2.660-1,111%
P/E RatioN/AN/A-
Revenue64.8M305K21,246%
Total Cash204M563M36%
Total Debt58M21.3M272%
FUNDAMENTALS RATINGS
ENTA vs VRDN: Fundamental Ratings
ENTA
VRDN
OUTLOOK RATING
1..100
6970
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6153
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
4550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (94) in the Biotechnology industry is in the same range as ENTA (95). This means that VRDN’s stock grew similarly to ENTA’s over the last 12 months.

VRDN's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as ENTA (100). This means that VRDN’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (98) in the Biotechnology industry is in the same range as VRDN (99). This means that ENTA’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (53) in the Biotechnology industry is in the same range as ENTA (61). This means that VRDN’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for VRDN (100). This means that ENTA’s stock grew significantly faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAVRDN
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
71%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FFIDX108.71N/A
N/A
Fidelity
CSVFX22.51N/A
N/A
Columbia International Div Inc Inst
PGUCX15.83N/A
N/A
Virtus Duff & Phelps Global Infras C
HCMQX21.57N/A
N/A
HCM Sector Plus I
RBCIX12.22N/A
N/A
RBC China Equity I

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with BEAM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-0.13%
BEAM - ENTA
38%
Loosely correlated
+7.66%
ADCT - ENTA
35%
Loosely correlated
+3.44%
VRDN - ENTA
35%
Loosely correlated
+3.61%
AKRO - ENTA
35%
Loosely correlated
-0.58%
ANAB - ENTA
34%
Loosely correlated
-3.77%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with AURA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+3.61%
AURA - VRDN
53%
Loosely correlated
+5.36%
SYRE - VRDN
51%
Loosely correlated
-0.13%
DSGN - VRDN
49%
Loosely correlated
-0.17%
CRNX - VRDN
48%
Loosely correlated
+0.98%
DNLI - VRDN
48%
Loosely correlated
+0.76%
More